Treatment of prostate cancer with biochemical recurrence after radical prostatectomy: a case report
10.3760/cma.j.cn112330-20210908-00015
- VernacularTitle:恩扎卢胺治疗根治性前列腺切除术后生化复发一例报告
- Author:
Yuyong WANG
1
;
Yixuan HU
Author Information
1. 浙江大学医学院附属杭州市第一人民医院泌尿外科，杭州 310006
- Keywords:
Prostate cancer;
Prostate specific antigen persistence;
Enzalutamide
- From:
Chinese Journal of Urology
2021;42(Z2):51-53
- CountryChina
- Language:Chinese
-
Abstract:
As a second-generation AR antagonist, enzalutamide has shown good effects in the treatment of castration-resistant prostate cancer, and has also been used in the treatment of hormone-sensitive prostate cancer. In 2018, a patient with prostate cancer was admitted to Hangzhou First People's Hospital. After radical prostatectomy, the patients was in PSA persistence. After 29 months of endocrine therapy, the patient developed drug resistance against bicalutamide, and PSA increased month by month. PSA dropped back to undetectable after changing bicalutamide to enzalutamine.
